Screening soil cultures for antimetabolite antitumor activity1) led to the isolation 2) of acivicin (Ia) (Fig. 1) . The unique enzyme-inhibiting and antitumor effects3) of acivicin led to its ongoing clinical trials by the National Cancer Institute. At one time, clinical formulations of NSC 163501 consisted of freeze-dried solutions of acivicin and mannitol adjusted to pH 7 with dilute alkali prior to lyophilization. In the course of such a formulation, an NCl contractor inadvertently added I N rather than 0.1 N alkali to a 200 g lot of acivicin. After 1 hour at pH 12 the solution was neutralized with HCl and lyophilized and the resulting solids returned to Upjohn for recovery of the acivicin. Pure acivicin was recovered in 89% yield by previously described tent-butyloxycarbonyl derivatization procedures.') This report describes the isolation and structure of a ninhydrin-positive contaminant formed in trace amounts by the alkaline treatment.
The contaminant was detected in mother liquor residues by TLC on Whatman LK6DF silica gel plates developed with propanol -ethyl acetate -water (4: 4: 3): the contaminant was observed at Rf 0.33, acivicin at Rf 0.40, and tricholomic acid (2a),5) (Fig. 1) , the normal alkaline hydrolysis product of acivicin,e) at Rf 0.16. Mother liquor residues were derivatized') and extracted with two portions of ethyl acetate after acidification. The first extract yielded homogeneous acivicin after acid regeneration and recrystallization. The second extract afforded 2.0 g of impure acivicin (88 % purity) and a mother liquor residue (2.06 g) consisting mainly of salt along with 159 mg of acivicin and the contaminant. This residue was chromatographed on silica gel with propanol -ethyl acetatewater (4: 4: 3) and collected fractions were monitored by weight and TLC. Pooling and evapo- A new carbon signal at 160.6 ppm was so broad that it was barely discernible. Structure 3a (Fig. 1) , resulting from the amino group of one acivicin molecule displacing the chloro group of another, is consistent with the observed spectra and would afford tricholomic acid on further hydrolysis.') Additional support for structure 3 was obtained by SCHOTTEN-BAUMANN benzoylation of the contaminant.
The chromatographic polarity, acidic-water solubility, and observed FAB-MS MW 424 of the benzoyl derivative were consistent with the monobenzoyl structure 3b (Fig.  1) , which is still an amino acid.
A sample of 3b purified to chromatographic homogeneity on silica gel resisted crystallization efforts but counter-current chromatography in the Ito phase, the oily residue was dissolved in 8 ml of a mixture of the phases and introduced into the coil through a loop valve. Lower phase was then used as the mobile phase at a flow rate of 4.6 ml/minute while the coil was rotated at 800 rpm. After the loss of 79 ml of stationary phase (retention 251 ml or 76%), collected fractions of the mobile phase were monitored by TLC densitometry. After 444 ml of mobile phase, homo- Since these needles were unsuited for X-ray diffraction studies, the structure of 3b was confirmed by additional NMR studies. Benzoyl acivicin (lb) prepared and purified by counter-current chromatography, using hexane -ethyl acetate -methanol -0.2 N acetic acid (1: 2: 1 : 2) with the upper phase as the mobile phase, was a clear, colorless gum. FAB-MS: (M-H)+ at 283. Benzoylation of tricholomic acid afforded a complex mixture from which a crystalline monobenzoyl derivative (2b) was isolated by chromatography and crystallization. MS: M+ at 264. NMR data on la, 1b, 2b, 3a and 3b is summarized in Table 1 . A well-defined signal at 159 ppm was assigned to carbon 6 of 3b.
Contaminant 3a retained only a trace of the antimicrobial activity of acivicin against Bacillas subtilis grown on a synthetic medium and was inactive against P388 leukemia in mice up to the highest dose tested (100 mg/kg, qd I x 5 schedule).
